Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Dierks

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
The Journal of Experimental Medicine|August 19, 2009
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migrationRebekka Grundler, Laurent Brault, Christelle Gasser, et al.
Plos One|December 31, 2016
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic LeukemiaMarco Benkisser-Petersen, Maike Buchner, Arlette Dörffel, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 2, 2021
Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert PerspectivesFrederik A Verburg, Holger Amthauer, Ina Binse, et al.
Molecular Cancer Therapeutics|March 25, 2014
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)Sarah Decker, Johannes Finter, Aaron James Forde, et al.
Frontiers in Endocrinology|September 3, 2021
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical RationalePia Adam, Stefan Kircher, Iuliu Sbiera, et al.
The Journal of Experimental Medicine|April 17, 2013
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Jonas S Jutzi, Ruzhica Bogeska, Gorica Nikoloski, et al.
Thyroid : Official Journal of the American Thyroid Association|January 29, 2021
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid CarcinomaChristine Dierks, Jochen Seufert, Konrad Aumann, et al.
Blood|January 25, 2023
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptomsAmelie Jaeger, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, et al.
Nature Communications|February 18, 2022
T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10Vidhya M Ravi, Nicolas Neidert, Paulina Will, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The Journal of Experimental Medicine|August 19, 2009
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migrationRebekka Grundler, Laurent Brault, Christelle Gasser, et al.
Plos One|December 31, 2016
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic LeukemiaMarco Benkisser-Petersen, Maike Buchner, Arlette Dörffel, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 2, 2021
Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert PerspectivesFrederik A Verburg, Holger Amthauer, Ina Binse, et al.
Molecular Cancer Therapeutics|March 25, 2014
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)Sarah Decker, Johannes Finter, Aaron James Forde, et al.
Frontiers in Endocrinology|September 3, 2021
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical RationalePia Adam, Stefan Kircher, Iuliu Sbiera, et al.
The Journal of Experimental Medicine|April 17, 2013
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Jonas S Jutzi, Ruzhica Bogeska, Gorica Nikoloski, et al.
Thyroid : Official Journal of the American Thyroid Association|January 29, 2021
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid CarcinomaChristine Dierks, Jochen Seufert, Konrad Aumann, et al.
Blood|January 25, 2023
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptomsAmelie Jaeger, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, et al.
Nature Communications|February 18, 2022
T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10Vidhya M Ravi, Nicolas Neidert, Paulina Will, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 4